Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.55 |
| ▸ | SCTR | P47872 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091176 | 0.96 | GLP1R (0.58) | GLP1RSCTR | |
| SCHEMBL30091379 | 0.96 | GLP1R (0.58) | GLP1RSCTR | |
| SCHEMBL30091292 | 0.95 | GLP1R (0.55) | GLP1RSCTR | |
| SCHEMBL30091171 | 0.95 | GLP1R (0.58) | GLP1RSCTR | |
| SCHEMBL30091122 | 0.95 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL30091165 | 0.94 | GLP1R (0.55) | GLP1RSCTR | |
| SCHEMBL30091278 | 0.94 | GLP1R (0.55) | GLP1RSCTR | |
| SCHEMBL30091352 | 0.94 | GLP1R (0.57) | GLP1RSCTR | |
| SCHEMBL30091298 | 0.93 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL30091268 | 0.93 | GLP1R (0.60) | GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | DARBIX LLC | 2024-08-01 | — | — | US | disclosed |
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO INC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | GLP1R, GIPR, IAPP | GLP1R 1/4885SCTR 9/4885 |
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | GLP1R, GIPR, IAPP | GLP1R 1/4885SCTR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.